



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 October 2017
EMA/699041/2017
Inspections, Human Medicines Pharmacovigilance & Committees Division

Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

Autologous human mesenchymal stem cells present in bone marrow cells suspension.

Brief description of the finished product

Cryopreserved human bone marrow-derived mononuclear cells.

Proposed indication

Treatment of type 2 *Diabetes Mellitus*.

EMA/CAT conclusion

The procedure was finalised on 4 April 2016 for the following recommendation.

On the basis that the product:



- contains cells that are not intended to be used for the same essential function(s) in the recipient and the donor;
- is presented as having properties for, or is administered to human beings with a view to treating a disease through the pharmacological, immunological or metabolic action of its cells,

the EMA/CAT considers that the product falls within the definition of a somatic cell therapy medicinal product as provided in Article 2(1) of Regulation (EC) 1394/2007.